 The investigators hypothesize that tumor cell killing by cytotoxic chemotherapy exposes the immune system to high levels of tumor antigens.The combination of PaclitaxelCarboplatin and Pembrolizumab will invigorate tumor-specific T-cell immunity in this setting by inhibiting PD-L1PD-1 signaling, and may result in deeper and more durable responses compared with standard chemotherapy alone. 